news

Our latest
Press Releases & Updates

Latest press releases

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI OCT Atlas® is now CE-marked under EU MDR 2017/745 for clinical use across AMD, Diabetic Retinopathy, DME, and Glaucoma, validated in the DILL study across 124 patients and three OCT devices.

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

EarlySight announces strategic collaboration with RetinAI to enhance clinical Insights from its Cellularis® Retinal Imaging Platform

EarlySight and Ikerian (RetinAI) have announced a new collaboration to integrate EarlySight’s Cellularis® imaging technology with RetinAI’s AI-driven Discovery® platform. Together, the companies aim to enhance retinal imaging and analysis for clinical and research use.

EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions

EssilorLuxottica has acquired Ikerian AG, the parent company of RetinAI, strengthening its med-tech strategy with advanced AI and data-driven solutions that enhance clinical workflows and improve patient care in ophthalmology.

Latest updates

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME

2 new Posters in ARVO 2021 Virtual

We are very excited of our team and collaborators presenting 2 posters in ARVO 2021! One Poster on 'Longitudinal analysis of Retinal Pigment Epithelium Atrophy progression using an automated segmentation algorithm' providing segmentation analysis over 5 years using deep learning,
and a poster on 'Automated fovea and optic disc detection in the presence of occlusions in Fundus SLO Images'.

New publication on TVST - Automated quantification of pathological fluids in neovascular age-related degeneration, and it's repeatability using deep learning

In this peer reviewed publication, we develop a reliable algorithm for the automated identification, localization, and volume measurement of exudative manifestations in neovascular age-related macular degeneration (nAMD), including intraretinal (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED), using a deep-learning approach. The deep-learning algorithm can simultaneously acquire a high level of performance for the identification and volume measurements of IRF, SRF, and PED in nAMD, providing accurate and repeatable predictions. Including layer segmentation during training and squeeze-excite block in the network architecture were shown to boost the performance. Source: Mantel et al. , TVST 2021, 10 (17) - https://doi.org/10.1167/tvst.10.4.17 Authors: Irmela Mantel; Agata Mosinska; Ciara Bergin; Maria Sole Polito; Jacopo Guidotti; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet

Translation Vision Science and Technology

RetinAI receives ISO 13485:2016 certification

Retinai has just received the ISO 13485 certification, a recognition awarded by regulatory bodies and necessary for companies willing to develop & commercialise Medical Devices. RetinAI Discovery, our platform for medical image and data management in ophthalmology, is now getting ready to be commercialised to clinics as a medical device. We are extremely proud of the team for achieving the certification!

Contact us for more informations! We are happy to hear from you!